MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib. MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib. We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors. Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin-like growth factor 1 (IGF1)/IGF2, HGF/MET and HER2/HER3 have been reported to activate the PI3K/AKT and RAS/RAF/MEK/ERK axis independently of EGFR [172,173].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [173]
In the citing paper
“The proto-oncogene MET, which enforces hepatocyte growth factor receptor (HGFR, also known as MET tyrosine kinase receptor), shares several downstream pathways with EGFR, including RAS/RAF/MAPK and PI3K/AKT signaling pathways [173,183].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [173]
In the citing paper
“MET activation, by either gene amplification or ligand stimulation, accounts for 5–10% of lung cancer resistance to EGFR TKIs [12,14].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [14]
In the citing paper
“MET amplification has been reported as a mechanism of resistance to gefitinib[8] and osimertinib[23]. In our cohort, it was identified in T790M-preserved (5/19) and T790M-loss (1/21) cases, and the second most common resistance mechanism after EGFR tertiary mutations (5/42, 14%).”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [8]
In the citing paper
“MET amplification has been reported as a mechanism of resistance to gefitinib[8] and osimertinib[23].”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [8]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,228
Self-citationEscape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 991
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 824
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Blanke, C. D., Demetri, G. D., Joensuu, H., Roberts, P. J., Eisenberg, B. L., von Mehren, M., Fletcher, C. D. M., Sandau, K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2265 · Cited by 814
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 705
Research works printed but not linked: 2
- J. G. Christensen et al., Cancer Res.63, 7345 (2003).
- F. M. Yakes et al., Cancer Res.62, 4132 (2002).
Cited by
Items 501–600 of 1,038
Vasan, N., & Cantley, L. C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00633-1 · Cited by 163
Self-citationKancha, R. K., von Bubnoff, N., Peschel, C., & Duyster, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1757 · Cited by 168
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
Linger, R. M., Keating, A. K., Earp, H. S., & Graham, D. K. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.515980 · Cited by 168
Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
Glickman, M. S., & Sawyers, C. L. (2012) · Cell · doi:10.1016/j.cell.2012.02.015 · Cited by 168
HER3 Is a Determinant for Poor Prognosis in Melanoma
Reschke, M., Mihic-Probst, D., van der Horst, E. H., Knyazev, P., Wild, P. J., Hutterer, M., Meyer, S., Dummer, R., Moch, H., & Ullrich, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0186 · Cited by 168
MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
Cepero, V., Sierra, J. R., Corso, S., Ghiso, E., Casorzo, L., Perera, T., Comoglio, P. M., & Giordano, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0436 · Cited by 167
Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.
Uramoto, H., Iwata, T., Onitsuka, T., Shimokawa, H., Hanagiri, T., & Oyama, T. (2010) · PubMed · Cited by 171
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Liu, C., Lu, H., Wang, H., Loo, A., Zhang, X., Yang, G., Kowal, C., Delach, S., Wang, Y., Goldoni, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2718 · Cited by 167
Self-citationPertuzumab: new hope for patients with HER2-positive breast cancer
Capelan, M., Pugliano, L., De Azambuja, E., Bozovic, I., Saini, K. S., Sotiriou, C., Loi, S., & Piccart-Gebhart, M. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mds328 · Cited by 166
Itraconazole Inhibits Angiogenesis and Tumor Growth in Non–Small Cell Lung Cancer
Aftab, B. T., Dobromilskaya, I., Liu, J. O., & Rudin, C. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0691 · Cited by 167
“such as c-MET (33, 34), constitutive activation of downstream pathways such as phosphoinositide 3-kinase (PI3K) and Akt (35, 36), as well as a large-scale shift in gene expression and morphology known as epithelial–mesenchymal transition (37, 38) have all been implicated as mechanisms of acquired resistance.”
Buonato, J. M., & Lazzara, M. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-12-4721 · Cited by 166
Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies
Bikker, J. A., Brooijmans, N., Wissner, A., & Mansour, T. S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8010542 · Cited by 166
Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
Lev, S. (2020) · Biochemical Society Transactions · doi:10.1042/bst20191055 · Cited by 163
Advances in the preclinical testing of cancer therapeutic hypotheses
Caponigro, G., & Sellers, W. R. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3385 · Cited by 165
Wang, S. E., Xiang, B., Guix, M., Olivares, M. G., Parker, J., Chung, C. H., Pandiella, A., & Arteaga, C. L. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00787-08 · Cited by 165
Xu, Y., Huang, J., Ma, L., Shan, J., Shen, J., Yang, Z., Liu, L., Luo, Y., Yao, C., & Qian, C. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.11.034 · Cited by 148
Baltschukat, S., Engstler, B. S., Huang, A., Hao, H.-X., Tam, A., Wang, H. Q., Liang, J., DiMare, M. T., Bhang, H.-E. C., Wang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2814 · Cited by 163
Yang, J.-J., Chen, H.-J., Yan, H.-H., Zhang, X.-C., Zhou, Q., Su, J., Wang, Z., Xu, C.-R., Huang, Y.-S., Wang, B.-C., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.09.016 · Cited by 164
Mechanisms of Acquired Resistance to Targeted Cancer Therapies
Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 164
Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Chang, T.-H., Tsai, M.-F., Su, K.-Y., Wu, S.-G., Huang, C.-P., Yu, S.-L., Yu, Y.-L., Lan, C.-C., Yang, C.-H., Lin, S.-B., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1440oc · Cited by 163
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale
Salgia, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0472 · Cited by 163
Maloney, E., Clark, C., Sivakumar, H., Yoo, K., Aleman, J., Rajan, S. A. P., Forsythe, S., Mazzocchi, A., Laxton, A. W., Tatter, S. B., et al. (2020) · Micromachines · doi:10.3390/mi11020208 · Cited by 161
Therapy-induced APOBEC3A drives evolution of persistent cancer cells
Isozaki, H., Sakhtemani, R., Abbasi, A., Nikpour, N., Stanzione, M., Oh, S., Langenbucher, A., Monroe, S., Su, W., Cabanos, H. F., et al. (2023) · Nature · doi:10.1038/s41586-023-06303-1 · Cited by 158
Self-citationBispecific antibody drug conjugates: Making 1+1>2
Gu, Y., Wang, Z., & Wang, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.01.009 · Cited by 159
Hatakeyama, H., Cheng, H., Wirth, P., Counsell, A., Marcrom, S. R., Wood, C. B., Pohlmann, P. R., Gilbert, J., Murphy, B., Yarbrough, W. G., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012702 · Cited by 162
Huang, C.-P., Tsai, M.-F., Chang, T.-H., Tang, W.-C., Chen, S.-Y., Lai, H.-H., Lin, T.-Y., Yang, J. C.-H., Yang, P.-C., Shih, J.-Y., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.08.021 · Cited by 161
Mechanistic Understanding of Curcumin’s Therapeutic Effects in Lung Cancer
Wan Mohd Tajuddin, W. N. B., Lajis, N. H., Abas, F., Othman, I., & Naidu, R. (2019) · Nutrients · doi:10.3390/nu11122989 · Cited by 162
Single-cell lipidomics with high structural specificity by mass spectrometry
Li, Z., Cheng, S., Lin, Q., Cao, W., Yang, J., Zhang, M., Shen, A., Zhang, W., Xia, Y., Ma, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23161-5 · Cited by 160
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Krall, E. B., Wang, B., Munoz, D. M., Ilic, N., Raghavan, S., Niederst, M. J., Yu, K., Ruddy, D. A., Aguirre, A. J., Kim, J. W., et al. (2017) · eLife · doi:10.7554/elife.18970 · Cited by 160
Self-citationCosta, D. B., Kobayashi, S., Tenen, D. G., & Huberman, M. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.017 · Cited by 160
“The acquired amplification of the MET oncogene was recently reported as occurring in around 20% of TKI-resistant patients [59].”
BackgroundKoh, J., Go, H., Keam, B., Kim, M.-Y., Nam, S. J., Kim, T. M., Lee, S.-H., Min, H. S., Kim, Y. T., Kim, D.-W., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.63 · Cited by 160
Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations
Wykosky, J., Fenton, T., Furnari, F., & Cavenee, W. K. (2011) · Chinese Journal of Cancer · doi:10.5732/cjc.010.10542 · Cited by 160
Acquired resistance to EGFR‐targeted therapies in colorectal cancer
Van Emburgh, B. O., Sartore-Bianchi, A., Di Nicolantonio, F., Siena, S., & Bardelli, A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.003 · Cited by 160
McDermott, U., Pusapati, R. V., Christensen, J. G., Gray, N. S., & Settleman, J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3620 · Cited by 161
Self-citationSystems biology approaches for advancing the discovery of effective drug combinations
Ryall, K. A., & Tan, A. C. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0055-9 · Cited by 159
Crosstalk of Oncogenic Signaling Pathways during Epithelial–Mesenchymal Transition
Lindsey, S., & Langhans, S. A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00358 · Cited by 159
Receptor Tyrosine Kinases and Targeted Cancer Therapeutics
Takeuchi, K., & Ito, F. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1774 · Cited by 159
Molecular biomarkers for lung adenocarcinoma
Calvayrac, O., Pradines, A., Pons, E., Mazières, J., & Guibert, N. (2017) · European Respiratory Journal · doi:10.1183/13993003.01734-2016 · Cited by 158
The Opposing Roles of PIK3R1/p85α and PIK3R2/p85β in Cancer
Vallejo-Díaz, J., Chagoyen, M., Olazabal-Morán, M., González-García, A., & Carrera, A. C. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.009 · Cited by 172
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
Cortot, A. B., & Jänne, P. A. (2014) · European Respiratory Review · doi:10.1183/09059180.00004614 · Cited by 158
Personalized medicine in lung cancer: what we need to know
Mok, T. S. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.126 · Cited by 158
Self-citationDeng, J., Shimamura, T., Perera, S., Carlson, N. E., Cai, D., Shapiro, G. I., Wong, K.-K., & Letai, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1961 · Cited by 158
Seipin: from human disease to molecular mechanism
Cartwright, B. R., & Goodman, J. M. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r023754 · Cited by 157
EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story
Sequist, L. V., & Lynch, T. J. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.090506.202405 · Cited by 158
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
Ma, C., Wei, S., & Song, Y. J. (2011) · PubMed · doi:10.3978/j.issn.2072-1439.2010.12.02 · Cited by 158
Self-citationWheeler, D. L., Iida, M., Kruser, T. J., Nechrebecki, M. M., Dunn, E. F., Armstrong, E. A., Huang, S., & Harari, P. M. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.8.7903 · Cited by 157
Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance
Shimamura, T., Li, D., Ji, H., Haringsma, H. J., Liniker, E., Borgman, C. L., Lowell, A. M., Minami, Y., McNamara, K., Perera, S. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5428 · Cited by 157
Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin β1/Src/Akt-Driven Bypass Signaling
Kanda, R., Kawahara, A., Watari, K., Murakami, Y., Sonoda, K., Maeda, M., Fujita, H., Kage, M., Uramoto, H., Costa, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4502 · Cited by 157
Cancer invasion and resistance: interconnected processes of disease progression and therapy failure
Alexander, S., & Friedl, P. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.11.003 · Cited by 182
Frogne, T., Benjaminsen, R. V., Sonne‐Hansen, K., Sørensen, B. S., Nexø, E., Lænkholm, A., Rasmussen, L. M., Riese, D. J., de Crémoux, P., Stenvang, J., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0011-8 · Cited by 157
The PI3-K/AKT-Pathway and Radiation Resistance Mechanisms in Non-small Cell Lung Cancer
Schuurbiers, O. C. J., Kaanders, J. H. A. M., van der Heijden, E. H. F. M., Dekhuijzen, R. P. N., Oyen, W. J. G., & Bussink, J. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a1084f · Cited by 160
Dziadziuszko, R., Wynes, M. W., Singh, S., Asuncion, B. R., Ranger-Moore, J., Konopa, K., Rzyman, W., Szostakiewicz, B., Jassem, J., & Hirsch, F. R. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318240ca0d · Cited by 156
Yamamoto, C., Basaki, Y., Kawahara, A., Nakashima, K., Kage, M., Izumi, H., Kohno, K., Uramoto, H., Yasumoto, K., Kuwano, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0043 · Cited by 155
MicroRNAs and Potential Targets in Osteosarcoma: Review
Sampson, V. B., Yoo, S., Kumar, A., Vetter, N. S., & Kolb, E. A. (2015) · Frontiers in Pediatrics · doi:10.3389/fped.2015.00069 · Cited by 160
The HER family and cancer: emerging molecular mechanisms and therapeutic targets
Sergina, N. V., & Moasser, M. M. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.10.002 · Cited by 184
Soucheray, M., Capelletti, M., Pulido, I., Kuang, Y., Paweletz, C. P., Becker, J. H., Kikuchi, E., Xu, C., Patel, T. B., Al-shahrour, F., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0377 · Cited by 154
Self-citationThe Microenvironment of Lung Cancer and Therapeutic Implications
Mittal, V., Rayes, T. E., Narula, N., McGraw, T. E., Altorki, N. K., & Barcellos‐Hoff, M. H. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_5 · Cited by 170
Emerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 166
MicroRNAs as therapeutic targets in chemoresistance
Garofalo, M., & Croce, C. M. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2013.05.001 · Cited by 153
Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 152
Ricordel, C., Friboulet, L., Facchinetti, F., & Soria, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx705 · Cited by 172
Hait, W. N., & Hambley, T. W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3836 · Cited by 168
Cancer Genes in Lung Cancer: Racial Disparities: Are There Any?
El-Telbany, A., & Ma, P. C. (2012) · Genes & Cancer · doi:10.1177/1947601912465177 · Cited by 175
Hata, A., Katakami, N., Yoshioka, H., Kaji, R., Masago, K., Fujita, S., Imai, Y., Nishiyama, A., Ishida, T., Nishimura, Y., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000647 · Cited by 161
c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas
Tsuta, K., Kozu, Y., Mimae, T., Yoshida, A., Kohno, T., Sekine, I., Tamura, T., Asamura, H., Furuta, K., & Tsuda, H. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318241655f · Cited by 152
MET alterations in NSCLC—Current Perspectives and Future Challenges
Remón, J., Hendriks, L. E. L., Mountzios, G., García‐Campelo, R., Saw, S. P. L., Uprety, D., Recondo, G., Villacampa, G. J., & Reck, M. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.10.015 · Cited by 167
Troiani, T., Martinelli, E., Napolitano, S., Vitagliano, D., Ciuffreda, L. P., Costantino, S., Morgillo, F., Capasso, A., Sforza, V., Nappi, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0423 · Cited by 150
ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer
Stern, D. F. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9083-7 · Cited by 168
De Rosa, V., Iommelli, F., Monti, M., Fonti, R., Votta, G., Stoppelli, M. P., & Del Vecchio, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0375 · Cited by 150
Meng, X., Zhao, Y., Han, B. R., Zha, C., Zhang, Y., Li, Z., Wu, P., Qi, T., Jiang, C., Liu, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14036-x · Cited by 161
Johnson, M. L., Garassino, M. C., Mok, T. S. K., & Mitsudomi, T. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.05.011 · Cited by 172
Self-citationBianco, R., Rosa, R., Damiano, V., Daniele, G., Gelardi, T., Garofalo, S., Tarallo, V., De Falco, S., Melisi, D., Benelli, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4905 · Cited by 149
Overcoming implementation challenges of personalized cancer therapy
Meric‐Bernstam, F., & Mills, G. B. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.127 · Cited by 173
USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer
Byun, S., Lee, S.-Y., Lee, J., Jeong, C.-H., Farrand, L., Lim, S., Reddy, K., Kim, J. Y., Lee, M.-H., Lee, H. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3696 · Cited by 147
Wang, J., Anderson, M. G., Oleksijew, A., Vaidya, K. S., Boghaert, E. R., Tucker, L., Zhang, Q., Han, E. K., Palma, J. P., Naumovski, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1568 · Cited by 145
Liao, B.-C., Lin, C.-C., & Yang, J. C.-H. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000164 · Cited by 145
Ware, K. E., Marshall, M. E., Heasley, L. R., Marek, L., Hinz, T. K., Hercule, P., Helfrich, B. A., Doebele, R. C., & Heasley, L. E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014117 · Cited by 146
Hammerman, P. S., Jänne, P. A., & Johnson, B. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0189 · Cited by 145
Self-citationWang, L., Cao, H., Liu, L., Wang, B., Walker, W. A., Acra, S. A., & Yan, F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.553800 · Cited by 146
Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy
Vosjan, M. J. W. D., Vercammen, J., Kolkman, J. A., Stigter-van Walsum, M., Revets, H., & van Dongen, G. A. M. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0891 · Cited by 146
Shi, P., Oh, Y.-T., Deng, L., Zhang, G., Qian, G., Zhang, S., Ren, H., Wu, G., Legendre, B., Anderson, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1574 · Cited by 142
Siwak, D. R., Carey, M. S., Hennessy, B. T., Nguyen, C. T. Y., Murray, M. M., Nolden, L. K., & Mills, G. B. (2009) · Journal of Oncology · doi:10.1155/2010/568938 · Cited by 156
Stahlhut, C. E., & Slack, F. J. (2015) · Cell Cycle · doi:10.1080/15384101.2014.1003008 · Cited by 155
Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer
Shi, J., Yao, D., Liu, W., Wang, N., Lv, H., Zhang, G., Ji, M., Li, X., He, N., Shi, B., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-50 · Cited by 145
Prospects for pharmacological targeting of pseudokinases
Kung, J. E., & Jura, N. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0018-3 · Cited by 139
Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer
Arienti, C., Pignatta, S., & Tesei, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01308 · Cited by 138
Lin, J. J., Choudhury, N. J., Yoda, S., Zhu, V. W., Johnson, T. W., Sakhtemani, R., Dagogo-Jack, I., Digumarthy, S. R., Lee, C., Do, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0032 · Cited by 145
Self-citationAmin, D. N., Campbell, M. R., & Moasser, M. M. (2010) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2010.08.007 · Cited by 144
Catenacci, D. V. T. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.09.011 · Cited by 144
Rho, J. K., Choi, Y. J., Kim, S. Y., Kim, T. W., Choi, E. K., Yoon, S.-J., Park, B. M., Park, E., Bae, J. H., Choi, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1103 · Cited by 152
Yi, Y., Zeng, S., Wang, Z., Wu, M., Ma, Y., Ye, X., Zhang, B., & Liu, H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.12.021 · Cited by 156
Kubo, T., Yamamoto, H., Lockwood, W. W., Valencia, I., Soh, J., Peyton, M., Jida, M., Otani, H., Fujii, T., Ouchida, M., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24150 · Cited by 143
Albrecht, B. K., Harmange, J.-C., Bauer, D., Berry, L., Bode, C., Boezio, A. A., Chen, A., Choquette, D. M., Dussault, I., Fridrich, C., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800043g · Cited by 143
Xia, W., Petricoin, E., Zhao, S., Liu, L.-H., Osada, T., Cheng, Q., Wulfkuhle, J. D., Gwin, W. R., Yang, X., Gallagher, R. I., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3480 · Cited by 153
Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance
Schrank, Z., Chhabra, G., Lin, L., Iderzorig, T., Osude, C., Khan, N., Kuckovic, A., Singh, S., Miller, R., & Puri, N. (2018) · Cancers · doi:10.3390/cancers10070224 · Cited by 143
Onitsuka, T., Uramoto, H., Nose, N., Takenoyama, M., Hanagiri, T., Sugio, K., & Yasumoto, K. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.022 · Cited by 147
Mechanisms of resistance to HER family targeting antibodies
Kruser, T. J., & Wheeler, D. L. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.01.009 · Cited by 156
Akhavan, D., Pourzia, A. L., Nourian, A. A., Williams, K. J., Nathanson, D. A., Babić, I., Villa, G. R., Tanaka, K., Nael, A., Yang, H., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0502 · Cited by 159
Lee, K. H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.001 · Cited by 149
Metadata
- Authors
- Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., & Jänne, P. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
- ORCID
- Venue
- Science
- Published
- 2007-05-18
- Volume
- 316
- Issue
- 5827
- Pages
- 1039-1043
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1998971866
- Cited by
- 4,496
- References
- 22
- Citations by year
- 2026: 97 · 2025: 109 · 2024: 123 · 2023: 136 · 2022: 152 · 2021: 191 · 2020: 182 · 2019: 214 · 2018: 269 · 2017: 288 · 2016: 291 · 2015: 375 · 2014: 349 · 2013: 369 · 2012: 345
- FWCI
- 207.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca111560-05)
- National Cancer Institute (R01-CA111560, P01CA089021, R01CA114465, P20CA090578, P20 CA 90578-02, 1K12CA87723-01, K08CA120060, K12CA087723)
- National Institute of General Medical Sciences (GM 41890, R01GM041890)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- MET amplification, gefitinib resistance, lung cancer, HER3, PI3K signaling, EGFR kinase inhibitors, erlotinib, drug resistance, ErbB receptors, MET oncogene
- MeSH terms
- Gefitinib, Proto-Oncogene Mas, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cricetulus, Enzyme Inhibitors, Gene Amplification, Cricetinae, Humans, Indoles, Lung Neoplasms, Phosphorylation, Proto-Oncogene Proteins, Quinazolines, Sulfones, Signal Transduction, CHO Cells, Receptors, Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Phosphatidylinositol 3-Kinases, Receptor, ErbB-3, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.